Drug intelligence / Profile preview

LM-2417 + lenvatinib

Development stage: Unknown
Lead developer: LaNova Medicines
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

LM-2417 + lenvatinib is an investigational combination therapy composed of LM-2417, a bispecific antibody targeting sodium-dependent phosphate transport protein 2B (NaPi-2b), and lenvatinib, an approved multi-kinase inhibitor. LM-2417 acts as a NaPi-2b inhibitor and is under clinical development for the treatment of advanced malignant solid tumors, aiming to exploit potential synergistic anti-tumor effects when combined with lenvatinib. Lenvatinib inhibits multiple receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR), leading to antiangiogenic and antiproliferative effects. The combination is being investigated in phase 1/2 clinical trials in patients with advanced solid tumors[1][3][10].

Other names: sodium-dependent phosphate transport protein 2B inhibitor + lenvatinib

Targets

SLC34A2 (Sodium-dependent phosphate transporter type IIb)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TNFRSF9 (CD137 extracellular domain)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on LM-2417 + lenvatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM-2417 + lenvatinib.

Explore the full profile